Latest News and Press Releases

- Study results indicate beneficial effects on airway hyperresponsiveness, remodeling and inflammation Geneva, Switzerland, March 27, 2023 – HpVac SA, a company developing novel preventive and...

- Significant expansion of allergy research expertise Geneva, Switzerland, November 23, 2022 – HpVac SA, a company developing novel preventive and therapeutic first-line therapies against...

New York, United States, Oct. 24, 2022 (GLOBE NEWSWIRE) -- According to a research report published by Spherical Insights & Consulting, the Global Allergy Immunotherapy Market Size to grow from...

- Major milestone for accelerating the development of HpVac-13 in allergic diseases Geneva, Switzerland, October 18, 2022 – HpVac SA, a company developing novel preventive and therapeutic...

NEWARK, Del, Aug. 26, 2022 (GLOBE NEWSWIRE) -- The global conjunctivitis market is anticipated to portray a phenomenal growth opportunity by exhibiting a 5.8% CAGR with a valuation of US$ 1825.8...

New York, Nov. 17, 2021 (GLOBE NEWSWIRE) -- A recent article in the peer-reviewed journal International Forum of Allergy and Rhinology reported the results of a survey offered to individuals with...

New York, July 23, 2020 (GLOBE NEWSWIRE) -- Allovate Therapeutics, a New York-based biotechnology company, announced today that it has extended its free Allerdent® program. Allerdent® is a...

New York, May 06, 2020 (GLOBE NEWSWIRE) -- Allovate Therapeutics, a New York-based biotechnology company, announced today that it is making its allergy immunotherapy delivery platform available...

New York, April 02, 2019 (GLOBE NEWSWIRE) -- Allovate Therapeutics (“Allovate®”), a New York-based biotechnology company focused on improving treatment for allergies, is pleased to announce the...

New York, March 08, 2019 (GLOBE NEWSWIRE) -- Allovate Therapeutics (“Allovate®”), a New York-based biotechnology company focused on improving treatment for allergies, is pleased to announce that the...